This is a Validated Antibody Database (VAD) review about human EIF3B, based on 5 published articles (read how Labome selects the articles), using EIF3B antibody in all methods. It is aimed to help Labome visitors find the most suited EIF3B antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
EIF3B synonym: EIF3-ETA; EIF3-P110; EIF3-P116; EIF3S9; PRT1; eukaryotic translation initiation factor 3 subunit B; eukaryotic translation initiation factor 3 subunit 9; eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD); eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa; prt1 homolog
Abcam
rabbit monoclonal (EPR5804) |
| Abcam EIF3B antibody (Abcam, ab133601) was used in western blot on human samples (fig 2c). Front Microbiol (2018) ncbi |
Bethyl
rabbit polyclonal |
| In order to develop reagents to study RNA binding proteins, Bethyl EIF3B antibody (Bethyl, A301-761A) was used in RNA immunoprecipitation on human samples . Mol Cell (2016) ncbi |
rabbit polyclonal |
| Bethyl EIF3B antibody (Bethyl, A301-761A) was used in western blot on human samples (fig 1a). Oncotarget (2015) ncbi |
rabbit polyclonal |
| In order to study the mechanisms by which eIF3 contributes to carcinogenesis, Bethyl EIF3B antibody (Bethyl, A301-761A) was used in immunoprecipitation on human samples (fig 1) and in western blot on human samples (fig 1). Nature (2015) ncbi |
Santa Cruz Biotechnology
mouse monoclonal (C-5) |
| Santa Cruz Biotechnology EIF3B antibody (Santa Cruz Biotechnology, Sc-137214) was used in immunocytochemistry on human samples at 1:100. J Virol (2013) ncbi |
Articles Reviewed
- Schipany K, Rosner M, Ionce L, Hengstschläger M, Kovacic B. eIF3 controls cell size independently of S6K1-activity. Oncotarget. 2015;6:24361-75 pubmed
articles
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments